Healthcare and Life Science
Insights from the UK Life Sciences Start-up Report 2025: Building bridges with China for mutual growth
Disclaimer: This article is for informational purposes only and reflects the author’s independent observations on the UK life sciences sector and international collaboration opportunities. It does not constitute investment advice. ...
First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant (branded as Lynkuet™) for the treatment of moderate to severe hot flushes and night sweats associated with menopause. These symptoms, also known as vasomotor symptoms, affect a significant pr...
Strategic momentum: Building UK–China bridges in life sciences through Wuhan
Disclaimer: This article reflects EFEC’s views and insights based on information available as of August 2025. While believed to be accurate, some data are estimates or projections and may change over time. It is provided for general information only and does not constitute professional,...
Study prompts global call on pituitary tumour research
Brain surgeons and researchers from Cambridge and London are calling on colleagues worldwide to adopt the first ever consistent way of recording outcomes following pituitary gland tumour removal. ...
China’s First National Medical Insurance Standard: £145bn Opportunity for UK Life Sciences
Insight from Excellence First Enterprise Consultancy (EFEC) Disclaimer: This article is for general information only and does not constitute professional, financial, or legal advice. Market projections are based on current data and subject to change. ...
Revenue growth continues - H1 and Q2 2025 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said:“Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readout...
Activated immune cells reveal hidden drivers of autoimmune diseases
By stimulating macrophages – a type of white blood cell – with biological factors that mimic infection, researchers have uncovered genetic drivers of complex diseases such as inflammatory bowel disease (IBD), in one of the largest studies of its kind. ...
Placing and subscription raising approximately £1.12 million, total voting tights and PDMR dealings
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that following the announcement of its interim results for the six months ended 30 June 2025 earl...
o2h Technology Announces Tech Kickstarter Competition 4.0 to Support Seed and Early-Stage Startups
Cambridge, UK: o2h Technology, a business vertical of the o2h Group, is delighted to announce the launch of the fourth edition of its Tech Kickstarter Competition. First launched in 2023, the initiative continues to support innovative seed and early-stage companies by helping them bring...
Unlocking Minds: China’s BCI Revolution and Opportunities for UK Collaboration
As members of Cambridge Network and Medilink Midlands, we are fascinated by the intersection of emerging technologies and global collaboration. Brain-computer interfaces (BCI)—technologies enabling direct brain-machine interaction—are a field where China’s rapid development presents exc...